Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Mindera Raises Over $12M Series A-2 Financing | ||
By: PR Newswire Association LLC. - 12 May 2021 | Back to overview list |
|
SAN DIEGO, May 12, 2021 /PRNewswire/ -- Mindera Corporation today announced a $12.6M Series A-2 capital raise. The round was led by Mountain Group Partners, Rockmont Investments, and Scientific Health Development. The funding will be used to commercialize Mind.Px, a groundbreaking tool to prospectively predict patient response to expensive psoriasis biologics, as well as continue development of the Mindera Dermal Intelligence™ Platform. The Mindera platform uses a simple patch that extracts biomarkers from the skin in minutes, allowing for rapid and painless extraction of RNA. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin at the exact moment of the test. In the case of Mind.Px, this rich patient-specific data is then analyzed by proprietary machine learning algorithms to predict the appropriate psoriasis biologic drug for a patient prior to therapeutic selection and treatment. Mind.Px is a first-of-its-kind precision medicine dermatology solution that aligns patient, physician, and payer interests by predicting effective biologics for individuals, avoiding trial-and-error prescription behavior and wasted payer spending. For more information, contact info@minderadx.com. About Mindera
View original content to download multimedia:http://www.prnewswire.com/news-releases/mindera-raises-over-12m-series-a-2-financing-301290062.html SOURCE Mindera Corporation |
||
|
||
Copyright 2021 PR Newswire Association LLC. | Back to overview list |